About Mana Bio
Mana.bio is an AI-based drug delivery startup that builds a platform for lipid nanoparticle (LNP) development to enable targeted delivery of nucleic acid therapeutics — including mRNA, DNA, and gene therapies — to extrahepatic tissues. The company integrates machine learning and nanotechnology to systematically design, test, and optimize LNP formulations, and has launched Mina™, the first LLM-powered AI agent built specifically for LNPs.
Company details
Funding
Total raised
$19.5M
Last stage
Seed
Investors
Founders
Avi Schroeder
Tenured Chemical Engineering professor at the Technion, expert in nanomedicine and drug delivery; postdoctoral research at Robert Langer's lab at MIT; holds 19 patents and 30+ awards.
Kira Radinsky
Professor and scientific advisor at Mana.bio, contributing expertise to the company's AI and drug delivery research.
Yogev Debbi
Co-founder and Chief Executive Officer of Mana.bio, leading the company's AI-powered drug delivery platform for RNA therapeutics.
LinkedIn
Roy Nevo
Co-founder and Chief Technology Officer at Mana.bio, expert in drug delivery and AI/ML integration for lipid nanoparticle development.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.